fluorogenic hdac substrate class iia (BPS Bioscience)
Structured Review
Fluorogenic Hdac Substrate Class Iia, supplied by BPS Bioscience, used in various techniques. Bioz Stars score: 94/100, based on 25 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fluorogenic+substrate/Fluorogenic+HDAC+class+2a+substrate/pm42966048-513-28-33
Average 94 stars, based on 25 article reviews
Images
Related Articles
Incubation:Article Title: Synthesis and Biological Evaluation of Novel 2-Aroyl Benzofuran-Based Hydroxamic Acids as Antimicrotubule Agents Article Snippet: Different concentrations of the compounds were incubated in a low-binding black 96-well plate with 30 ng of human recombinant HDAC6 (BPS Bioscience, San Diego, CA, USA; Cat. # 50056), human recombinant HDAC1 (BPS Bioscience; Cat. # 50051), human recombinant HDAC8 (BPS Bioscience; Cat. # 50008), or 500 ng of human recombinant HDAC10 (BPS Bioscience; Cat. # 50060) in an assay buffer containing 25 mM Tris/HCl, pH 8.0, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl 2 , and 0.1 mg/mL bovine serum albumin for 30 min at 37 °C. .. At the end of the incubation, the deacetylation reaction was initiated by adding 200 μM of the fluorogenic acetylated HDAC substrate 3 (BPS Bioscience; Cat. # 50037) for the HDAC6, HDAC1, and HDAC10 assays, or of the Article Title: New Vanillyl-capped HDAC inhibitors exhibit anti-tumor efficacy in neuroblastoma and glioblastoma cells. Article Snippet: Histone deacetylases 6 and 8 (HDAC6/8) have emerged as promising therapeutic targets in aggressive neural tumors such as neuroblastoma and glioblastoma.. Herein, we report the design, synthesis, and comprehensive biological evaluation of a novel series of hydroxamic acid-based inhibitors (5a–p), featuring nature-inspired vanillyl CAP groups.. Structure–activity relationship (SAR) analysis, supported by molecular docking, elucidated the role of CAP, connecting unit, and linker structure, alongside zinc-binding group orientation, on isoform selectivity and potency. Article Title: Synthesis and Biological Evaluation of Novel 2-Aroyl Benzofuran-Based Hydroxamic Acids as Antimicrotubule Agents. Article Snippet: Different concentrations of the compounds were incubated in a low-binding black 96-well plate with 30 ng of human recombinant HDAC6 (BPS Bioscience, San Diego, CA, USA; Cat. # 50056), human recombinant HDAC1 (BPS Bioscience; Cat. # 50051), human recombinant HDAC8 (BPS Bioscience; Cat. # 50008), or 500 ng of human recombinant HDAC10 (BPS Bioscience; Cat. # 50060) in an assay buffer containing 25 mM Tris/HCl, pH 8.0, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, and 0.1 mg/mL bovine serum albumin for 30 min at 37 ◦C. .. At the end of the incubation, the deacetylation reaction was initiated by adding 200 μM of the fluorogenic acetylated HDAC substrate 3 (BPS Bioscience; Cat. # 50037) for the HDAC6, HDAC1, and HDAC10 assays, or of the Article Title: Spirotetrahydroisoquinoline-Based Histone Deacetylase Inhibitors as New Antifibrotic Agents: Biological Evaluation in Human Fibroblasts from Bronchoalveolar Lavages of Idiopathic Pulmonary Fibrosis Patients. Article Snippet: Human HDAC inhibition assays For the evaluation of their inhibitory activity, different concentrations of the compounds were incubated in a low-binding black 96-well plate with 30 ng of human recombinant HDAC6 (BPS Bioscience, San Diego, CA, USA; Cat. # 50056), human recombinant HDAC1 (BPS Bioscience; Cat. # 50051), human recombinant HDAC8 (BPS Bioscience; Cat. # 50008), 4ng of human recombinant HDAC3 (BPS Bioscience, Cat. # 50003), 6 ng of human recombinant HDAC5 (BPS Bioscience, Cat. # 50005) or 500 ng of human recombinant HDAC10 (BPS Bioscience; Cat. # 50060) or 100 ng human recombinant HDAC11 (BPS Bioscience, Cat. # 50021) in an assay buffer composed of 25 mM Tris/HCl, pH 8.0, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, and 0.1 mg/mL bovine serum albumin for 30 min at 37 °C. .. At the end of the incubation, the deacetylation reaction was initiated by adding 200 μM of the fluorogenic acetylated HDAC substrate 3 (BPS Bioscience; Cat. # 50037) for HDAC6, HDAC1, HDAC3 and HDAC10 assays, or of the Article Title: Reversing TGF-β1-induced fibrotic phenotype in human lung fibroblasts using a PROTAC tool derived from an indoline-based HDAC6 inhibitor Article Snippet: For the evaluation of their inhibitory activity, different concentrations of the compounds were incubated in a low-binding black 96-well plate with 30 ng of human recombinant HDAC6 (BPS Bioscience, San Diego, CA, USA; Cat. # 50056), human recombinant HDAC1 (BPS Bioscience; Cat. # 50051), human recombinant HDAC8 (BPS Bioscience; Cat. # 50008), or 500 ng of human recombinant HDAC10 (BPS Bioscience; Cat. # 50060) in an assay buffer composed of 25 mM Tris/HCl, pH 8.0, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, and 0.1 mg/mL bovine serum albumin for 30 min at 37 ◦C. .. At the end of the incubation, the deacetylation reaction was initiated by adding 200 μM of the fluorogenic acetylated HDAC substrate 3 (BPS Bioscience; Cat. # 50037) for HDAC6, HDAC1 and HDAC10 assays, or of the |

